Tumor necrosis factor-α inhibitors for the treatment of four cases of hidradenitis suppurativa

2021 ◽  
Keyword(s):  
Tumor Necrosis Factor ◽  
Hidradenitis Suppurativa ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals A case report about adalimumab-induced radiologically isolated syndrome: A significant side effect of tumour necrosis factor inhibitors

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110030
Author(s):  
Joshua Onasanya ◽  
Renée A Beach
Keyword(s):  
Tumor Necrosis Factor ◽  
Hidradenitis Suppurativa ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Inflammatory Diseases ◽  
Neurological Symptoms ◽  
Close Monitoring ◽  
Radiologically Isolated Syndrome ◽  
Factor Α ◽  
Necrosis Factor

Tumor necrosis factor-α antagonists have become a therapeutic mainstay for various inflammatory diseases including Hidradenitis Suppurativa. Despite their clinical efficacy, these medications have been associated with the rare development of demyelinating diseases. We report a 29-year-old male who developed neurological symptoms while taking adalimumab, a tumor necrosis factor-α antagonist, for treatment of Hidradenitis Suppurativa. The patient was subsequently diagnosed with radiologically isolated syndrome based on magnetic resonance imaging findings. The exact temporal relationship between demyelinating disease and tumor necrosis factor-α antagonists is poorly understood. Also, there remain a few effective treatment options for severe inflammatory diseases like Hidradenitis Suppurativa. In cases where a patient exhibits clinical stability and structural resolution following the development of neurological symptoms after tumor necrosis factor-α antagonist therapy, and there is a lack of other effective treatments to control extensive inflammatory disease, restarting the tumor necrosis factor-α antagonist could be considered provided there is neurology approval and close monitoring.

scholarly journals Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa

2018 ◽  
Vol 10 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Farida Benhadou ◽  
Guillaume Hellgren ◽  
Fabienne Willaert ◽  
Véronique del Marmol
Keyword(s):  
Tumor Necrosis Factor ◽  
Inflammatory Response ◽  
Hidradenitis Suppurativa ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Tnf Α ◽  
Adalimumab Therapy ◽  
Factor Α ◽  
First Time ◽  
Necrosis Factor

Tumor necrosis factor-α (TNF-α) normally binds to TNF-α receptors, leading to the inflammatory response of autoimmune diseases. Adalimumab is a TNF-inhibiting, anti-inflammatory, biological medication which binds to TNF-α, thus reducing this inflammatory response. The use of TNF-α-inhibiting medication, such as adalimumab, being the first FDA-approved treatment for hidradenitis suppurativa, has drastically changed the management of dermatological diseases. One rarely reported manifestation that occurs as a side effect associated with the use of TNF-α-blocking agents is erythroderma. This study, for the first time, reports the case of a patient suffering from hidradenitis suppurativa with concomitant psoriasis, who developed a severe and acute erythrodermic rash after the start of adalimumab therapy.

Sign in / Sign up

Export Citation Format

Share Document